SOLICITATION NOTICE
Q -- analyze data from the Boston Collaborative Drug Surveillance Program (BCDSP)’s licensed copy of the UK Clinical Practice Research Datalink (CPRD)
- Notice Date
- 9/5/2013
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- NCI-130083-EB
- Archive Date
- 10/4/2013
- Point of Contact
- Erin M. Breedlove, Phone: 2402765387, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
breeerin@mail.nih.gov, ninans@mail.nih.gov
(breeerin@mail.nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E136, Bethesda, MD 20892, UNITED STATES Description National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB), plans to procure on a sole source basis services to analyze data from the Boston Collaborative Drug Surveillance Program (BCDSP)'s licensed copy of the UK Clinical Practice Research Datalink (CPRD), from Boston Collaborative Drug Surveillance Program, 85E. Newton Street, M-921, Office of Sponsored Program-Med., Boston, MA 02118. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the business size standard is $14m. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. NCI DECG requires the contractor to analyze data from the Boston Collaborative Drug Surveillance Program (BCDSP)'s licensed copy of the UK Clinical Practice Research Datalink (CPRD). The goal will be to conduct a series of nested case-control studies to examine the associations between metabolic syndrome with and without a prior history of GERD or PPI prescriptions and the subsequent development of Barrett's esophagus and esophageal cancer. Barrett's esophagus is a precancerous lesion that is considered to principally arise as a complication of gastroesophageal reflux disease (GERD) and has the effect of drastically increasing the risk of esophageal adenocarcinoma. Risk factors for esophageal adenocarcinoma include GERD, tobacco smoking, and obesity, although the mechanism of the latter remains unclear. The mechanical effect of obesity is widely accepted, culminating in a higher propensity for GERD and subsequent increased risk of Barrett's esophagus. However, evidence suggests that increasing central adiposity also increases risk of Barrett's esophagus independent of GERD. Related to central adiposity is metabolic syndrome which is a confluence of risk factors known to contribute to a systemic inflammatory state; a potential indirect mechanism by which obesity could be associated with Barrett's esophagus. In a recent SEER-Medicare analysis, NCI demonstrated that metabolic syndrome increased risk of Barrett's esophagus, an association driven by and confined to the stratum without GERD symptoms. To further investigate these hypotheses and extend upon recent findings, NCI will assess these relationships in the Clinical Practice Research Datalink (CPRD). The CPRD is a vast database of longitudinal medical records in the United Kingdom that is able to provide more accurate exposure assessment, a much larger age-range for study, and greater generalizability of results with implications for preventive health.  The project will consist of three nested case-control studies within the Clinical Practice Research Database (CPRD). Comparisons will be made between 1) Barrett's esophagus cases and population controls, 2) esophageal cancer cases with prior Barrett's esophagus and population controls, and 3) esophageal cancer cases with prior Barrett's esophagus and Barrett's esophagus controls. Each control group will be selected by incidence-density sampling based on date of diagnosis and matched on age, sex, general practice, and years of history in the database. In addition reflux status, sex, or both will be evaluated for effect modification of the association. The BCDSP is the only known group which can provide the analysis of the CPRD data using globally-validated standards of research conduct and utilizing the licensed copy of CPRD. The epidemiology team at the Boston Collaborative Drug Surveillance Program (BCDSP) is experts on using CPRD and identifying appropriate usage of READ codes. The CPRD contains over 85,000 READ codes. These codes have changed overtime as well as their usage patterns. The BCDSP team has conducted CPRD-related analyses since the inception of the CPRD and can provide a working knowledge of the database. In addition to their vast number of studies utilizing CRPD data their previous research has included identifying GERD and PPI prescriptions within CPRD. The BCDSP's carefully curated database of validated READ codes for GERD diagnoses and PPI prescriptions will be essential to the study. Their extensive expertize and prior comprehensive exposure assessment projects and lists will provide NCI gains in efficiency. The NCI DCEG has an ongoing CPRD project with BCDSP, and some of the SAS modules developed under this project can be directly utilized in the proposed project. These modules are specific to the way in which BCDSP format and manipulate the CPRD data for use in analyses. This notice is not a request for competitive quotation. However, if any interested party especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11 AM EST, on September 19, 2013. All responses and questions must be in writing and faxed 240-276-5399 or emailed to Erin Breedlove Contract Specialist via electronic mail at breeein@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: NCI-130083-EB on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-130083-EB/listing.html)
- Record
- SN03176721-W 20130907/130906000536-6ed24faebf1d00aac1ad409037af58b4 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |